Metformin therapy in a hyperandrogenic anovulatory mutant murine model with polycystic ovarian syndrome characteristics improves oocyte maturity during superovulation

Journal of Ovarian Research

Volumn 4, Issue 1, 2011, Pages

  Sabatini, Mary E ^a   Guo, Lankai ^a   Lynch, Maureen P ^a   Doyle, Joseph O ^a   Lee, Hojoon ^a   Rueda, Bo R ^a   Styer, Aaron K ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

hyperinsulinemia; metformin; oocyte; polycystic ovarian syndrome; superovulation

Indexed keywords

LEPTIN; METFORMIN; PROGESTERONE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANOVULATION; ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; FEMALE; GLUCOSE INTOLERANCE; GRANULOSA CELL; HYPERANDROGENISM; INSULIN RESISTANCE; LUTEINIZATION; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OOCYTE DEVELOPMENT; OOCYTE MATURATION; OVARY POLYCYSTIC DISEASE; PHENOTYPE; PRIORITY JOURNAL; SUPEROVULATION;

EID: 79956220308     PISSN: None     EISSN: 17572215     Source Type: Journal    
DOI: 10.1186/1757-2215-4-8     Document Type: Article

References (55)

1. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod 2004 19 41 47 14688154
2. Diagnosis, epidemiology, and genetics of the polycystic ovary syndrome. MO Goodarzi R Azziz, Best Pract Res Clin Endocrinol Metab 2006 20 193 205 10.1016/j.beem.2006.02.005 16772151 (Pubitemid 43842923)
3. Polycystic ovarian syndrome (PCOS) and insulin resistance. KH Park JY Kim CW Ahn YD Song SK Lim HC Lee, Int J Gynaecol Obstet 2001 74 261 267 10.1016/S0020-7292(01)00442-8 11543750 (Pubitemid 32785661)
4. Prevalence and characteristics of the metabolic syndrome in women with polycystic ovary syndrome. T Apridonidze PA Essah MJ Iuorno JE Nestler, J Clin Endocrinol Metab 2005 90 1929 1935 10.1210/jc.2004-1045 15623819 (Pubitemid 40586223)
5. Evidence for an association between metabolic cardiovascular syndrome and coronary and aortic calcification among women with polycystic ovary syndrome. EO Talbott JV Zborowski JR Rager MY Boudreaux DA Edmundowicz DS Guzick, J Clin Endocrinol Metab 2004 89 5454 5461 10.1210/jc.2003-032237 15531497 (Pubitemid 39518426)
6. The association between polycystic ovaries and endometrial cancer. OC Pillay LF Te Fong JC Crow E Benjamin T Mould W Atiomo PA Menon AJ Leonard P Hardiman, Hum Reprod 2006 21 924 929 16361289
7. Expression of insulin-like growth factor (IGF), IGF-binding protein, and IGF receptor messenger ribonucleic acids in normal and polycystic ovaries. R Voutilainen S Franks HD Mason H Martikainen, J Clin Endocrinol Metab 1996 81 1003 1008 10.1210/jc.81.3.1003 8772565 (Pubitemid 26083961)
8. Pulsatile luteinizing hormone patterns in the follicular phase of the menstrual cycle, polycystic ovarian disease (PCOD) and non-PCOD secondary amenorrhea. CW Burger T Korsen H van Kessel PA van Dop FJ Caron J Schoemaker, J Clin Endocrinol Metab 1985 61 1126 1132 10.1210/jcem-61-6-1126 3932449 (Pubitemid 16186713)
9. Opioidergic regulation of LH pulsatility in women with polycystic ovary syndrome. SL Berga SS Yen, Clin Endocrinol (Oxf) 1989 30 177 184 10.1111/j.1365-2265.1989.tb03739.x (Pubitemid 19063222)
10. Polycystic ovary syndrome. DA Ehrmann, N Engl J Med 2005 352 1223 1236 10.1056/NEJMra041536 15788499
11. A practical approach to the diagnosis of polycystic ovary syndrome. RJ Chang, Am J Obstet Gynecol 2004 191 713 717 10.1016/j.ajog.2004.04.045 15467530
12. Characterization of groups of hyperandrogenic women with acanthosis nigricans, impaired glucose tolerance, and/or hyperinsulinemia. A Dunaif M Graf J Mandeli V Laumas A Dobrjansky, J Clin Endocrinol Metab 1987 65 499 507 10.1210/jcem-65-3-499 3305551 (Pubitemid 17131438)
13. Role of hyperinsulinemia in the pathogenesis of the polycystic ovary syndrome, and its clinical implications. JE Nestler, Semin Reprod Endocrinol 1997 15 111 122 10.1055/s-2007-1016294 9165656 (Pubitemid 27217222)
14. Metformin for the treatment of the polycystic ovary syndrome. RL Barbieri AR Gargiulo, Minerva Ginecol 2004 56 63 79 14973411 (Pubitemid 38313782)
15. Outlook: metformin use in infertile patients with polycystic ovary syndrome: an evidence-based overview. S Palomba R Oppedisano A Tolino F Orio F Zullo, Reprod Biomed Online 2008 16 327 335 10.1016/S1472-6483(10)60592-5 18339252 (Pubitemid 351419450)
16. Metformin in polycystic ovary syndrome: systematic review and meta-analysis. JM Lord IH Flight RJ Norman, BMJ 2003 327 951 953 10.1136/bmj.327.7421.951 14576245
17. Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancy. EM Velazquez S Mendoza T Hamer F Sosa CJ Glueck, Metabolism 1994 43 647 654 10.1016/0026-0495(94)90209-7 8177055 (Pubitemid 24145474)
18. Clomiphene citrate versus metformin as first-line approach for the treatment of anovulation in infertile patients with polycystic ovary syndrome. S Palomba F Orio Jr A Falbo T Russo A Tolino F Zullo, J Clin Endocrinol Metab 2007 92 3498 3503 10.1210/jc.2007-1009 17595241 (Pubitemid 47435326)
19. Effect of metformin taken in the 'fresh' in vitro fertilization/ intracytoplasmic sperm injection cycle upon subsequent frozen embryo replacement in women with polycystic ovary syndrome. C Brewer S Acharya F Thake T Tang A Balen, Hum Fertil (Camb) 2010 13 134 142 10.3109/14647273.2010.504805
20. Use of metformin in polycystic ovary syndrome: a meta-analysis. AA Creanga HM Bradley C McCormick CT Witkop, Obstet Gynecol 2008 111 959 968 10.1097/AOG.0b013e31816a4ed4 18378757 (Pubitemid 351482630)
21. Clomiphene, metformin, or both for infertility in the polycystic ovary syndrome. RS Legro HX Barnhart WD Schlaff BR Carr MP Diamond SA Carson MP Steinkampf C Coutifaris PG McGovern NA Cataldo,, et al. N Engl J Med 2007 356 551 566 10.1056/NEJMoa063971 17287476 (Pubitemid 46220816)
22. Metformin treatment before and during IVF or ICSI in women with polycystic ovary syndrome. LO Tso MF Costello LE Albuquerque RB Andriolo V Freitas, Cochrane Database Syst Rev 2009 D006105
23. Role of AMP-activated protein kinase in mechanism of metformin action. G Zhou R Myers Y Li Y Chen X Shen J Fenyk-Melody M Wu J Ventre T Doebber N Fujii,, et al. J Clin Invest 2001 108 1167 1174 11602624 (Pubitemid 32995375)
24. AMP-activated protein kinase is activated by low glucose in cell lines derived from pancreatic beta cells, and may regulate insulin release. IP Salt G Johnson SJ Ashcroft DG Hardie, Biochem J 1998 335 Pt 3 533 539 9794792 (Pubitemid 28515405)
25. Role of AMP-activated protein kinase in the regulation by glucose of islet beta cell gene expression. G da Silva Xavier I Leclerc IP Salt B Doiron DG Hardie A Kahn GA Rutter, Proc Natl Acad Sci USA 2000 97 4023 4028 10.1073/pnas.97.8.4023 10760274 (Pubitemid 30226080)
26. AMP-kinase regulates food intake by responding to hormonal and nutrient signals in the hypothalamus. Y Minokoshi T Alquier N Furukawa YB Kim A Lee B Xue J Mu F Foufelle P Ferre MJ Birnbaum,, et al. Nature 2004 428 569 574 10.1038/nature02440 15058305 (Pubitemid 38480541)
27. AMP-activated protein kinase plays a role in the control of food intake. U Andersson K Filipsson CR Abbott A Woods K Smith SR Bloom D Carling CJ Small, J Biol Chem 2004 279 12005 12008 14742438 (Pubitemid 38445761)
28. Leptin stimulates fatty-acid oxidation by activating AMP-activated protein kinase. Y Minokoshi YB Kim OD Peroni LG Fryer C Muller D Carling BB Kahn, Nature 2002 415 339 343 10.1038/415339a 11797013 (Pubitemid 34087557)
29. Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. T Yamauchi J Kamon Y Minokoshi Y Ito H Waki S Uchida S Yamashita M Noda S Kita K Ueki,, et al. Nat Med 2002 8 1288 1295 10.1038/nm788 12368907 (Pubitemid 35373562)
30. Effects of adenosine monophosphate-activated kinase activators on bovine oocyte nuclear maturation in vitro. S Bilodeau-Goeseels M Sasseville C Guillemette FJ Richard, Mol Reprod Dev 2007 74 1021 1034 10.1002/mrd.20574 17290417 (Pubitemid 47012797)
31. Adenosine 5'-monophosphate kinase-activated protein kinase (PRKA) activators delay meiotic resumption in porcine oocytes. MA Mayes MF Laforest C Guillemette RB Gilchrist FJ Richard, Biol Reprod 2007 76 589 597 10.1095/biolreprod.106.057828 17167165 (Pubitemid 46466515)
32. AMPK regulation of mouse oocyte meiotic resumption in vitro. J Chen E Hudson MM Chi AS Chang KH Moley DG Hardie SM Downs, Dev Biol 2006 291 227 238 10.1016/j.ydbio.2005.11.039 16443210
33. Metformin-induced stimulation of adenosine 5' monophosphate-activated protein kinase (PRKA) impairs progesterone secretion in rat granulosa cells. L Tosca P Solnais P Ferre F Foufelle J Dupont, Biol Reprod 2006 75 342 351 10.1095/biolreprod.106.050831 16760380 (Pubitemid 44268068)
34. Effects of metformin on bovine granulosa cells steroidogenesis: possible involvement of adenosine 5' monophosphate-activated protein kinase (AMPK). L Tosca C Chabrolle S Uzbekova J Dupont, Biol Reprod 2007 76 368 378 10.1095/biolreprod.106.055749 17123942
35. Metformin decreases IGF1-induced cell proliferation and protein synthesis through AMP-activated protein kinase in cultured bovine granulosa cells. L Tosca C Rame C Chabrolle S Tesseraud J Dupont, Reproduction 2010 139 409 418 10.1530/REP-09-0351 19906888
36. Pharmacokinetic-pharmacodynamic modeling for the relationship between glucose-lowering effect and plasma concentration of metformin in volunteers. SH Lee KI Kwon, Arch Pharm Res 2004 27 806 810 10.1007/BF02980152 15357011
37. The influence of genetic background on the expression of the obese (Ob) gene in the mouse. DL Coleman KP Hummel, Diabetologia 1973 9 287 293 10.1007/BF01221856 4588246
38. Obese and diabetes: two mutant genes causing diabetes-obesity syndromes in mice. DL Coleman, Diabetologia 1978 14 141 148 10.1007/BF00429772 350680 (Pubitemid 8286141)
39. Food intake, water intake, and drinking spout side preference of 28 mouse strains. AA Bachmanov DR Reed GK Beauchamp MG Tordoff, Behav Genet 2002 32 435 443 10.1023/A:1020884312053 12467341 (Pubitemid 35364856)
40. Ovarian follicle counts - not as simple as 1, 2, 3. JL Tilly, Reprod Biol Endocrinol 2003 1 11 10.1186/1477-7827-1-11 12646064
41. Ovulatory response to treatment of polycystic ovary syndrome is associated with a polymorphism in the STK11 gene. RS Legro HX Barnhart WD Schlaff BR Carr MP Diamond SA Carson MP Steinkampf C Coutifaris PG McGovern NA Cataldo,, et al. J Clin Endocrinol Metab 2008 93 792 800 18000088 (Pubitemid 351398555)
42. Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis. A Dunaif, Endocr Rev 1997 18 774 800 10.1210/er.18.6.774 9408743 (Pubitemid 28009567)
43. Polycystic ovary syndrome in asian women. EH Yu Ng PC Ho, Semin Reprod Med 2008 26 14 21 10.1055/s-2007-992920 18181078
44. Effect of clomifene citrate plus metformin and clomifene citrate plus placebo on induction of ovulation in women with newly diagnosed polycystic ovary syndrome: randomised double blind clinical trial. E Moll PM Bossuyt JC Korevaar CB Lambalk F van der Veen, BMJ 2006 332 1485 10.1136/bmj.38867.631551.55 16769748
45. Polycystic ovary syndrome in the Indian Subcontinent. GN Allahbadia R Merchant, Semin Reprod Med 2008 26 22 34 10.1055/s-2007-992921 18181079
46. Metformin inhibits aromatase via an extracellular signal-regulated kinase-mediated pathway. S Rice L Pellatt K Ramanathan SA Whitehead HD Mason, Endocrinology 2009 150 4794 4801 10.1210/en.2009-0540 19574398
47. Serum and follicular fluid levels of soluble Fas, soluble Fas ligand and apoptosis of luteinized granulosa cells in PCOS patients undergoing IVF. G Onalan B Selam Y Baran M Cincik R Onalan U Gunduz AU Ural R Pabuccu, Hum Reprod 2005 20 2391 2395 10.1093/humrep/dei068 15932917 (Pubitemid 41222482)
48. Leptin concentrations in patients with polycystic ovary syndrome before and after met-formin treatment depending on insulin resistance, body mass index and androgen con-centrations - introductory report. A Marciniak J Nawrocka-Rutkowska A Brodowska R Sienkiewicz I Szydlowska A Starczewski, Folia Histochem Cytobiol 2009 47 323 328 10.2478/v10042-009-0032-0 19995720
49. Insulin action in the normal and polycystic ovary. S Franks C Gilling-Smith H Watson D Willis, Endocrinol Metab Clin North Am 1999 28 361 378 10.1016/S0889-8529(05)70074-8 10352923 (Pubitemid 29242718)
50. Stimulation of lactate production in human granulosa cells by metformin and potential involvement of adenosine 5' monophosphate-activated protein kinase. MC Richardson S Ingamells CD Simonis IT Cameron R Sreekumar A Vijendren L Sellahewa S Coakley CD Byrne, J Clin Endocrinol Metab 2009 94 670 677 10.1210/jc.2008-2025 19001513
51. Systemic and local effects of metformin administration in patients with polycystic ovary syndrome (PCOS): relationship to the ovulatory response. S Palomba A Falbo T Russo F Orio A Tolino F Zullo, Hum Reprod 2010 25 1005 1013 10.1093/humrep/dep466 20106839
52. A unique rodent model of cardiometabolic risk associated with the metabolic syndrome and polycystic ovary syndrome. D Shi MK Dyck RR Uwiera JC Russell SD Proctor DF Vine, Endocrinology 2009 150 4425 4436 10.1210/en.2008-1612 19470707
53. A new rat model exhibiting both ovarian and metabolic characteristics of polycystic ovary syndrome. L Manneras S Cajander A Holmang Z Seleskovic T Lystig M Lonn E Stener-Victorin, Endocrinology 2007 148 3781 3791 10.1210/en.2007-0168 17495003 (Pubitemid 47105840)
54. The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin. RJ Shaw KA Lamia D Vasquez SH Koo N Bardeesy RA Depinho M Montminy LC Cantley, Science 2005 310 1642 1646 10.1126/science.1120781 16308421 (Pubitemid 41780780)
55. Phosphorylation and activation of AMP-activated protein kinase (AMPK) by metformin in the human ovary requires insulin. LJ Pellatt S Rice HD Mason, Endocrinology 2011 152 1112 1118 10.1210/en.2009-1429 21209024